Loading...
01/10 19:53
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reflects several negative aspects: declining EPS and EBITDA, increased operating expenses, and significant benefits costs. Despite share repurchases and dividends, the financial performance is weak. The Q&A reveals uncertainty about client onboarding and profitability of the Workday partnership, with unclear management responses. Market uncertainty and economic concerns further dampen outlook. The stock, with a market cap of $3.44 billion, is likely to experience a negative reaction in the range of -2% to -8% over the next two weeks.
Adjusted EPS $1.57, down from $2.00 in Q1 2024, primarily due to higher than expected benefits costs.
Adjusted EBITDA $102,000,000, down from $120,000,000 in Q1 2024, primarily due to higher than expected benefits costs.
Average number of paid worksite employees 306,023, up 0.7% from 303,000 in Q1 2024, but slightly below guidance due to delays and cancellations of new client starts.
Gross profit per worksite employee $338 per month, down from $378 in Q1 2024, due to an 8.4% increase in benefits costs per covered employee.
Benefits costs per covered employee Increased by 8.4% year-over-year, exceeding budget by $28,000,000, with $12,000,000 related to higher runoff of medical claims and $16,000,000 related to higher medical claims incurred in Q1.
Operating expenses Increased by $5,000,000 or 2% over Q1 2024, driven by investment in Workday strategic partnership totaling $13,000,000 in Q1 2025.
Cash dividends paid $23,000,000 in Q1 2025.
Shares repurchased 224,000 shares at a cost of $19,000,000 in Q1 2025.
Adjusted cash at quarter end $124,000,000.
Available credit facility $280,000,000.
New Joint Solution: Insperity and Workday have launched a corporate Workday platform, marking a significant milestone in their strategic partnership. The joint solution is expected to target mid-market businesses, potentially doubling Insperity's annual mid-market sales production.
Market Sentiment: Client sentiment has shifted negatively due to macroeconomic factors, with 66% of surveyed clients expecting a negative impact on their business, up from 29% in January. This has led to delays in onboarding new clients.
Operational Efficiency: Operating expenses were managed slightly below budget, with a 2% increase year-over-year. Investment in the Workday partnership totaled $13 million in Q1 2025.
Strategic Partnership: Insperity is focusing on leveraging its Workday partnership to enhance service offerings and improve market positioning, with a go-to-market plan in place for the new joint solution.
Higher Benefits Costs: The company reported higher than expected benefits costs, exceeding budget by $28 million, primarily due to increased medical claims and claims runoff from prior periods.
Macroeconomic Uncertainty: The new administration's economic policies led to uncertainty, causing delays or cancellations in onboarding new clients, impacting growth in paid worksite employees.
Client Sentiment: A client survey indicated that 66% of respondents expect a negative economic impact on their business, up from 29% earlier in the year, affecting hiring and sales.
Regulatory Pressures: Government actions related to tariffs and other policies created turbulence in the market, leading to a sudden reversal of optimism among small and mid-sized businesses.
Healthcare Market Volatility: The healthcare market has shown increased volatility since COVID, affecting predictability in claims processing and costs.
Operational Costs: Operating expenses increased slightly, driven by investments in the Workday strategic partnership, which may impact profitability.
Future Cost Management: The company is implementing pricing adjustments and evaluating benefit plan changes to mitigate rising healthcare costs and improve profitability.
Sales and Retention Challenges: Sales in March fell below budget due to market uncertainty, impacting the overall growth trajectory for the year.
Workday Strategic Partnership: Insperity has made significant progress on its Workday strategic partnership, including the launch of its corporate Workday platform in March 2025 and the development of a go-to-market plan for a joint solution.
Client Retention: Insperity achieved a client retention rate of 91% in Q1 2025, indicating strong customer loyalty and satisfaction.
Sales and Marketing Initiatives: The company has seen a double-digit increase in marketing leads and is focused on enhancing its sales efforts to drive growth.
Healthcare Cost Management Initiatives: Insperity is implementing three initiatives to address rising healthcare costs, including a pricing initiative, evaluation of plan design changes, and accelerated contract renewal discussions with UnitedHealthcare.
2025 Worksite Employee Growth: Insperity has reduced its expected worksite employee growth rate to 0.5% to 3% for 2025, down from initial guidance.
2025 Adjusted EBITDA: The company is forecasting full-year adjusted EBITDA in the range of $190 million to $245 million.
2025 Adjusted EPS: Insperity expects full-year adjusted EPS to be in the range of $2.23 to $3.28.
Q2 2025 Guidance: For Q2 2025, Insperity forecasts average paid worksite employees to be between 308,000 and 311,000, with adjusted EBITDA in the range of $33 million to $53 million.
Cash Dividends Paid: $23,000,000 in cash dividends paid during Q1 2025.
Share Repurchase: Repurchased 224,000 shares of stock at a cost of $19,000,000 in Q1 2025.
The earnings call revealed disappointing financial results with an EPS miss and lower EBITDA due to high benefits costs. Despite a positive outlook for 2026, the immediate financials are concerning. The Q&A highlighted management's optimism about future recovery and strong sales, but did not address current issues effectively. With a market cap of ~$3.4 billion, the negative financial results and uncertainty in guidance are likely to lead to a negative stock price movement in the short term.
The earnings call presents a mixed picture: strong client retention and efficient sales are positive, but reduced growth guidance and declining gross profit per employee are concerns. The Q&A reveals optimism about future growth and strategic initiatives, yet lacks concrete guidance on the Workday partnership's financial impact. The partnership with Workday and share repurchases provide some optimism, but increased healthcare costs and uncertain future projections temper enthusiasm. Given the market cap of $3.44 billion, the stock price is likely to remain stable, resulting in a neutral prediction.
The earnings call reveals several negative factors: disappointing financial results with missed EPS and EBITDA guidance, higher-than-expected benefits costs, and delays in client onboarding. The Q&A section highlights uncertainties due to government actions and healthcare cost volatility, with management providing unclear responses. Despite some positive elements like share repurchases and a strategic partnership with Workday, the immediate outlook is clouded by these challenges. Given the market cap and the negative sentiment from analysts, the stock price is likely to see a negative reaction in the range of -2% to -8%.
The earnings call reflects several negative aspects: declining EPS and EBITDA, increased operating expenses, and significant benefits costs. Despite share repurchases and dividends, the financial performance is weak. The Q&A reveals uncertainty about client onboarding and profitability of the Workday partnership, with unclear management responses. Market uncertainty and economic concerns further dampen outlook. The stock, with a market cap of $3.44 billion, is likely to experience a negative reaction in the range of -2% to -8% over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
